Delving into the Latest Updates on GB006, Inc. with Synapse

概览

关联

1

项与 GB006, Inc. 相关的临床试验

NCT04060342 / Terminated临床1期

A Phase 1/2, First-in-Human, Open-label, Dose Escalation Study of GB1275 Monotherapy and in Combination With an Anti-PD-1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma, Followed by Basket Expansion of GB1275 With Standard of Care or in Combination With an Anti-PD-1 Antibody in Patients With Specified Metastatic Solid Tumors

This first-in-human (FIH ) study is an open-label, multicenter study that consists of a Phase 1 Dose Escalation/Expansion phase of GB1275 monotherapy or in combination with Anti-PD-1 Antibody or in combination with Standard of Care in Patients with Metastatic Pancreatic Adenocarcinoma followed by a Phase 2 Basket Expansion phase in Patients with Specified Metastatic Solid Tumors

开始日期2019-08-13

申办/合作机构

GB006, Inc.

[+1]

100 项与 GB006, Inc. 相关的临床结果

登录后查看更多信息

0 项与 GB006, Inc. 相关的专利（医药）

登录后查看更多信息

100 项与 GB006, Inc. 相关的药物交易

登录后查看更多信息

100 项与 GB006, Inc. 相关的转化医学

登录后查看更多信息